■ New frontier in focal therapy for prostate cancer: prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging
Celeste Manfredi, Esaú Fernández-Pascual, Estefanía Linares-Espinós, et al
World J Clin Oncol.2021, vol 12(2): 61–68
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918526/
■ Biomarker in active surveillance for prostate cancer: a systematic review
Cécile Manceau, Gaëlle Fromont, Jean-Baptiste Beauval, et al
on behalf of the CC-AFU, Cancerology Committee of the Association Française d’Urologie
Cancers (Basel) 2021, vol 13(17): 4251
https://www.mdpi.com/2072-6694/13/17/4251/htm
■ A review on the current treatment paradigm in high-risk prostate cancer
Laura Burgess, Soumyajit Roy, Scott Morgan, Shawn Malone
Cancers (Basel) 2021, vol 13(17): 4257
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428221/
■ The relationship between overactive blasser and prostate cancer: a scoping review
Asher Khan, R. Trafford Crump, Kevin V. Carlson, Richard J. Baverstock
Can Urol Assoc J.2021, vol 15(9): E501–E509
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490099/
■ Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostactomy? A systematic review and meta-analysis
Ameeta L. Nayak, Anathea S. Flaman, Ranjeeta Mallick et al
Can Urol Assoc J 2021, vol 15(8): 269–279
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418268/
■ Prostate cancer – focus on cholesterol
Lucija Škara, Ana Huđek Turković, Ivan Pezelj, et al
Cancers (Basel) 2021, vol 13(18): 469
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469848/
■ Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol
Katharina Beyer, Lisa Moris, Michael Lardas et al
The PIONEER Consortium
BMJ Open.2021, vol 11(2): e040531
https://bmjopen.bmj.com/content/11/2/e040531
■ A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy
Amy Pawson, Zonia Ghumman, Phillip H. Kuo et al
Can Urol Assoc J.2020, vol 14(4): 130–138
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7124170/
■ A review of prostate cancer treatment impact on the CNS and cognitive function
Charles Ryan, Jeffrey S. Wefel, Alicia K. Morgans
Prostate Cancer Prostatic Dis.2020, vol 23(2): 207–219.
https://www.nature.com/articles/s41391-019-0195-5
■ Diagnosing hereditary cancer predisposition in men with prostate cancer
Mary Pritzlaff, Yuan Tian, Patrick Reineke et al
Genet Med.2020, vol 22(9): 1517–152
https://www.nature.com/articles/s41436-020-0830-5
■ Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Rebeca Lozano, Elena Castro, Isabel M. Aragón et al
Br J Cancer. 2021, vol 124(3): 552–563
https://www.nature.com/articles/s41416-020-01114-x
■ Shift work and prostate cancer: an updated systematic review and meta-analysis
Mario Rivera-Izquierdo, Virginia Martínez-Ruiz, Elena Mercedes Castillo-Ruiz et al
Int J Environ Res Public Health. 2020 Feb; 17(4): 1345
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068593/
■ Metastatic hormone-sensitive prostate cancer (mHSPC): Advances ad treatment strategies in the first-line setting
Kenrick Ng, Shievon Smith, Jonathan Shamash
Oncol Ther.2020, vol 8(2): 209–230
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020773/
■ Zinc deficiency in men over 50 and its implications in prostate disorder
Ann Katrin Sauer, Hector Vela, Guillermo Vela, Peter Stark, Eduardo Barrera-Juarez, Andreas M. Grabrucker
Front Oncol.2020, vol 0: 1293
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424038/
■ PARP inibitors in prostate and urothelial cancers
Rohan Garje, Raju Kumar Vaddepally, Yousef Zakharia
Front Oncol.2020, vol 10: 114
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020773/
■ Current and future management of locally advanced and metastatic prostate cancer
Neal D. Shore
Rev Urol.2020 vol 22(3): 110–123.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672503/
■ Can epigentic and inflammatory biomarkers identify clinically aggressive prostate cancer?
Pedro Bargão Santos, Hitendra Patel, Rui Henrique, Ana Félix
World J Clin Oncol.2020, vol 11(2): 43–52
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046922/
■ Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancerNavid Sobhani, Marianna Sirico, Daniele Generali, Fabrizio Zanconati, Bruna Scaggiante
World J Clin Oncol.2020, vol 11(7): 450–46
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407926/
■ What chance do we have to decrease prostate cancer overdiagnosis and overtreatment? A narrative review
Francesco Ziglioli, Giorgia Granelli, Domenico Maria Cavalieri, Tommaso Bocchialini, Umberto Maestroni
Acta Biomed. 2019; vol 90(4): 423–426
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233784/
■ Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis
E J Bass, A Pantovic, M J Connor et al
Prostate Cancer and Prostatic Diseases 2021
https://www.nature.com/articles/s41391-021-00449-7
■ Clinical considerations for the management of androgen indifferent prostate cancer
J E Berchuck, P V Viscuse, H Beltran, A Aparicio
Prostate Cancer Prostatic Dis 2021, vol 24 (3): 623-637
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353003/
■ Associations of fat and muscle with overall survival in men with prostate cancer: a systemic review with meta-analysis
P Lopez, R U Newton, D R Taafee et al
Prostate Cancer and Prostatic Diseases 2021
https://www.nature.com/articles/s41391-021-00442-0
■ PROMISE: a real-world clinical-genomic database ,to address knowledge gaps in prostate cancer
V S Koshkin, V G Patel, R Mckay
Prostate Cancer and Prostatic Diseases 2021
https://www.nature.com/articles/s41391-021-00433-1
■ Dietary interventions to improve body composition in men treated with androgen deprivation therapy for prostate cancer: a solution for the growing problem?
L Umlauff, M Weber, N Freitag et al
Prostate Cancer and Prostatic Diseases 2021
https://www.nature.com/articles/s41391-021-00411-7
■ Overall survival and adverse events after treatment with darolutamide vs. apalutamid vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
M Wenzel, L Nocera, C C Ruvolo et al
Prostate Cancer and Prostatic Diseases 2021
https://www.nature.com/articles/s41391-021-00395-4
■ 18F-fluciclovine P/CT performance in biochemical recurrence of prostate cancer: a systematic review
S Rais-Bahrami, J A Efstathiou, C M Turnbull et al
Prostate Cancer and Prostatic Diseases 2021
https://www.nature.com/articles/s41391-021-00382-9
■ How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
J Sultz, L Fong
Prostate Cancer and Prostatic Diseases 2021, vol 24: 697-717
https://www.nature.com/articles/s41391-021-00340-5
■ Treating the patient and not just the cancer: therapeutic burden in prostate cancer
D E Spratt, N Shore, O Sartor et al
Prostate Cancer and Prostatic Diseases 2021, vol 24: 647-661
https://www.nature.com/articles/s41391-021-00328-1
■ Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis
F Urabe, S Kimura, S Yamamoto et al
Prostate Cancer and Prostatic Diseases 2021, vol 24: 638-646
https://www.nature.com/articles/s41391-021-00329-0
■ Treatment of non metastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
F Saad, M Bögemann, K Suzuki, N Shore
Prostate Cancer and Prostatic Diseases 2021, vol 24: 323-334
https://www.nature.com/articles/s41391-020-00310-3
■ Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis
S Singh, C M Moore, S Punwani et al
Prostate Cancer and Prostatic Diseases 2021, vol 24: 612-622
https://www.nature.com/articles/s41391-021-00323-6
■ Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
A Hussain, A Tripathi, C Peiczonka et al
Prostate Cancer and Prostatic Diseases 2021, vol 24: 290-300
https://www.nature.com/articles/s41391-020-00296-y
■ The role of magnetic resonance imaging in active surveillance of prostate cancer
O A Alagbe, A C Westphalen, V F Muglia
Radiologia Brasileira 2021, vol 54 (4): 246-253
https://www.scielo.br/j/rb/a/MjNT69nsVxQN4w3cy39Gnhh/?lang=en
■ Androgen deprivation in prostate cancer: benefits of home based resistance training
T Lam, B Cheema, A Hayden et al
Sports Medicine – Open 2020, vol 6: 59
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736381/
■ Repeat radiation for local recurrence of head and neck tumors and in prostate cancer
Arne Grün, Thomas Kuhnt, Thorsten Schlomm et al
Dtsch Arztebl Int.2020, vol 117(10): 167–174
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171476/
■ Castration-resistant prostate cancer: current status of therapy with Radium-223 associated with anti-androgens (enzalutamide and abiraterone) – a systematic review
D A Added Filho, M S Benedetto Filho,
Revista de Medicina 2016, vol 95 (2)
https://www.revistas.usp.br/revistadc/article/view/116011/119961
■ Câncer de próstata: Artigos de Revisão I (Prostate Cancer: Reviews I)
Arquivo Blog Internet Médica – outubro 2019
https://internetmedica.com.br/cancer-de-prostata-artigos-de-revisao-online-prostate-cancer-reviews/
out 2019
■ Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil
Tel: 33245518
CRMMG: 7026
Email: pfleite1873@gmail.com
Blog Internet Médica – www.internetmedica.com.br
Data: outubro 2021